The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy

References

• Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA guidelines for the evaluation and man-agement of chronic heart failure in the adult: Executive Sum-mary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guide-lines (Committee to Revise the 1995 Guidelines for the Eval-uation and Management of Heart Failure). Circulation 2001; 104: 2996–3007.
   Google Scholar
• Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88:107-15.
   Google Scholar
• Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.
   Google Scholar
• Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kuhn ML. Role of neurohormonal mechanisms in deter-mining survival in patients with severe chronic heart failure. Circulation 1987; 75(5 Pt 2): IV80-92.
   Google Scholar
• Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91: 2573–81.
   Google Scholar
• Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370–7.
   Google Scholar
• Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metab-olism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580–8.
   Google Scholar
• Lopaschuk GD. Optimizing cardiac energy metabolism: a new approach to treating ischemic heart disease. Eur Heart J 1999; 1 Suppl 0: 032-9.
   Google Scholar
• Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207–12.
   Google Scholar
• Vitale C, Wajngaten M, Sposato B, Gebara 0, Rossini P, Fini M, Volterrani M, Rosano GM. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814–21.
   Google Scholar
• D’hahan N, Taouil K, Dassouli A, Morel JE. Long-term therapy with trimetazidine in cardiomyopathic Syrian ham-ster BIO 14:6. Eur J Pharmacol 1997; 328: 163–74.
   Google Scholar
• Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898–901.
   Google Scholar
• Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16.
   Google Scholar
• Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimen-sional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358–67.
   Google Scholar
• Guyatt GH, Sullivan MJ, Thompson PL, Fallen EL, Pugs-ley SO, Taylor DW, Berman LB. The six-minute walk test: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919–23.
   Google Scholar
• Knox AJ, Morrison JF, Muers ME Reproducibility of walk-ing test results in chronic obstructive airways disease. Tho-rax 1988; 43: 388–92.
   Google Scholar
• Shah MR, Hasselblad V, Gheorghiade M, Adams KF Jr, Swedberg K, Calif RM, O’Connor CM. Prognostic useful-ness of the six-minute walk in patients with advanced con-gestive heart failure secondary to ischemic or non-ischemic cardiomyopathy. Am J Cardiol 2001; 88: 987–93.
   Google Scholar
• Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galanti G, Gensini GF. Prognostic value of 6-min walk cor-ridor test in patients mild to moderate heart failure: com-parison with other methods of functional evaluation. Eur J Heart Fail 2003; 5: 247–52.
   Google Scholar
• Cazeau S, Leclerc C, Lavergne T, Walker S, Varna C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. Multisite Stimulationin in Car-diomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. New Engl J Med 2001; 344: 873–80.
   Google Scholar
• Sisakian HS. New therapeutic approach in chronic heart fail-ure: metabolic intervention with trimetazidine. Heart and Metabolism 2005; 26: 23–6.
   Google Scholar
• Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J2001; 22: 2164–70.
   Google Scholar
• Di Napoli P, Taccardi AA, Barsotti A. Long-term cardio-protective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated car-diomyopathy. Heart 2005; 91: 161–5.
   Google Scholar
• Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146: E18.
   Google Scholar
• Lopaschuk GP. Modulation of energy metabolism as an approach to treating heart failure. Cardiovasc J S Afr 2004; 15 suppl 45: 52.
   Google Scholar
• Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Reg-ulation of myocardial carbohydrate metabolism under nor-mal and ischemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243–57.
   Google Scholar
• Renaud JF. Internal pH, Na + and Ca2 + regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988; 1: 677–86.
   Google Scholar
• Randle PJ, Newsholme EA, Garland PB. Regulation of glu-cose uptake by muscle. Biochem J 1964; 93: 652–65.
   Google Scholar
• King LM, Opie LH. Glucose and glycogen utilization in myocardial ischemia—changes in metabolism and conse-quences for the myocyte. Mol Cell Biochem 1998; 180: 3–26.
   Google Scholar
• Williams FM, Tanda K, Kus M, Williams TI Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828–33.
   Google Scholar
• Knight C, Fox K. From antianginal drugs to myocardial cytoprotective agents. Am J Cardiol 1995; 76: 4B-7B.
   Google Scholar
• Boffa GM, Zaninotto M, Nalli C, Forth M, Tiso E, Raz-zolini R, Plebani M. Plasma levels of tumor necrosis fac-tor-alpha correlate with the six-minute walk test results in patients with mild to moderate heart failure. Ital Heart J 2004; 5: 48–52.
   Google Scholar
• LeMaitre JP, Harris S, Fox KA, Denvir M. Change in cir-culating cytokines after 2 forms of exercise training in chronic stable heart failure. Am Heart J 2004; 147: 100–5.
   Google Scholar